Compared to the placebo, patients treated with Kisunla had a 35% slower cognitive and functional decline at 18 months of ...

Alzheimer’s drug, donanemab (marketed as Kisunla), could be rejected for use by the National Health Service (NHS) in Britain, ...

Eli Lilly (NYSE: LLY) has been on a winning streak recently, with shares popping up by roughly 60% since the start of 2024 ...

Several people in fresno were among the first in the nation to receive a new treatment for alzheimer's disease.Now patients ...

In a groundbreaking move, the FDA has approved a new drug, Kisunla (donanemab-azbt) which is a once-a-month injectable ...

In July, the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease, which includes mild cognitive ...

Several Alzheimer’s patients in Fresno became some of the first in the nation to receive a new drug just approved by the FDA.

After Eli Lilly received Food and Drug Administration approval for Alzheimer’s drug Kisunla last month, a company exec was quoted as saying the drugmaker “really needs to raise awareness that there ...

Kisunla (donanemab-azbt) is a brand-name injection for IV infusion prescribed for Alzheimer’s disease. Kisunla has no known interactions with alcohol, other drugs, or supplements. However ...

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. This drug currently isn’t known to interact with other drugs. Note: As a person’s ...

Kisunla (donanemab-azbt) is a prescription drug that’s used to treat Alzheimer’s disease in adults. Kisunla is given as an intravenous (IV) infusion by a doctor or other healthcare professional.

Kisunla (donanemab-azbt) is a brand-name drug that’s prescribed for Alzheimer’s disease in adults. Kisunla comes as a solution for intravenous infusion that’s given by a healthcare professional.